MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-16-2026
Oragenics Net Income 2011-2026 | OGEN
Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.
Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]
It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.
The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.
Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.
It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.
However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.
Annual Net Income Oragenics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -9.84 M | -10.6 M | -20.7 M | -14.3 M | -15.7 M | -26.4 M | -15.6 M | -9.91 M | -6.73 M | -7.01 M | -11.7 M | -5.79 M | -16.1 M | -13.1 M | -7.68 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -5.79 M | -26.4 M | -12.7 M |
Quarterly Net Income Oragenics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -3.07 M | -2.27 M | -2.22 M | - | -2.46 M | -2.31 M | -2.45 M | - | -2.01 M | -3.05 M | -2.84 M | - | -3.87 M | -3.59 M | -4.59 M | - | -4.38 M | -3.82 M | -5.22 M | -4.41 M | -4.5 M | -12.3 M | -5.19 M | -3.6 M | -3.84 M | -4.81 M | -3.33 M | -2.76 M | -2.76 M | -2.28 M | -2.12 M | -1.46 M | -2.07 M | -1.22 M | -1.98 M | -2.67 M | -1.96 M | -313 K | -2.06 M | -2.22 M | -1.86 M | -6.34 M | -1.29 M | -1.22 M | -1.03 M | -1.9 M | -1.64 M | -3.08 M | -9.33 M | -2.07 M | -1.59 M | -1.99 M | -2.56 M | -6.93 M | 1.62 M | -1.94 M | -1.81 M | -2.37 M | -1.56 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.62 M | -12.3 M | -3 M |
References
- Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.
Net Income of other stocks in the Biotechnology industry
| Issuer | Net Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-514 M | - | 2.43 % | $ 254 M |  Germany |
 |
ARCA biopharma
ABIO
|
-83.7 M | - | 1052.0 % | $ 415 M |  USA |
 |
Verastem
VSTM
|
-209 M | $ 5.04 | -4.73 % | $ 349 M | USA |
 |
Voyager Therapeutics
VYGR
|
-120 M | $ 3.96 | -4.12 % | $ 232 M | USA |
 |
VistaGen Therapeutics
VTGN
|
-51.4 M | $ 0.57 | -5.87 % | $ 17.6 M | USA |
 |
Aeterna Zentaris
AEZS
|
-8.37 M | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
-19.2 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-155 M | - | - | $ 1.01 B | USA |
 |
AIkido Pharma
AIKI
|
-14.7 M | - | 1.93 % | $ 17.4 M | USA |
 |
Akouos
AKUS
|
-86.7 M | - | 0.23 % | $ 488 M | USA |
 |
Akero Therapeutics
AKRO
|
-252 M | - | - | $ 3.67 B | USA |
 |
I-Mab
IMAB
|
-1.47 B | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
603 M | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
67.3 M | - | 2.54 % | $ 160 B |  France |
 |
Albireo Pharma
ALBO
|
-34 M | - | -0.23 % | $ 916 M | USA |
 |
Biophytis SA
BPTS
|
-31.2 M | - | -13.47 % | $ 169 M | France |
 |
Aileron Therapeutics
ALRN
|
-49.9 M | - | 10.36 % | $ 9.8 M | USA |
 |
Aptinyx
APTX
|
-64.8 M | - | -39.0 % | $ 4.57 M | USA |
 |
Midatech Pharma plc
MTP
|
-5.46 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-8.09 M | - | -1.52 % | $ 24.7 M | USA |
 |
Arena Pharmaceuticals
ARNA
|
-616 M | - | -6.81 % | $ 3.04 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-18.4 M | - | - | $ 26.5 M | USA |
 |
Avenue Therapeutics
ATXI
|
-11.7 M | - | -52.27 % | $ 4.45 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-38 M | - | - | $ 7.46 M |  Israel |
 |
Atreca
BCEL
|
-97.2 M | - | -11.76 % | $ 5.79 M | USA |
 |
Acorda Therapeutics
ACOR
|
-253 M | - | -24.86 % | $ 820 K | USA |
 |
bluebird bio
BLUE
|
-212 M | - | - | $ 546 M | USA |
 |
Acasti Pharma
ACST
|
-9.57 M | - | 4.01 % | $ 150 M | Canada |
 |
Институт стволовых клеток человека
ISKJ
|
72.9 M | - | - | - |  Russia |
 |
Avid Bioservices
CDMO
|
-141 M | - | - | $ 789 M | USA |
 |
Adverum Biotechnologies
ADVM
|
-131 M | - | - | $ 86.2 M | USA |
 |
Acer Therapeutics
ACER
|
-26.2 M | - | 2.71 % | $ 14 M | USA |
 |
Advaxis
ADXS
|
-48.1 M | - | -9.65 % | $ 45.9 M | USA |
 |
Adaptive Biotechnologies Corporation
ADPT
|
-59.5 M | $ 12.41 | -11.1 % | $ 1.88 B | USA |
 |
Wave Life Sciences Ltd.
WVE
|
-204 M | $ 6.37 | 2.66 % | $ 1.07 B |  Singapore |
 |
Xenetic Biosciences
XBIO
|
-2.68 M | $ 2.72 | -2.86 % | $ 4.63 M | USA |
 |
XBiotech
XBIT
|
-45.5 M | $ 2.27 | -1.73 % | $ 69.2 M | USA |
 |
Xenon Pharmaceuticals
XENE
|
-234 M | $ 54.48 | -1.89 % | $ 4.24 B | Canada |
 |
Xeris Pharmaceuticals
XERS
|
554 K | $ 5.4 | -3.05 % | $ 866 M | USA |
 |
X4 Pharmaceuticals
XFOR
|
-79.2 M | $ 4.04 | -6.26 % | $ 171 M | USA |
 |
Xencor
XNCR
|
-91.9 M | $ 11.42 | -7.23 % | $ 848 M | USA |
 |
XOMA Corporation
XOMA
|
31.7 M | $ 30.17 | -1.18 % | $ 364 M | USA |
 |
BeiGene, Ltd.
BGNE
|
287 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
22nd Century Group
XXII
|
-5.05 M | $ 2.41 | -18.03 % | $ 444 K | USA |
 |
BioDelivery Sciences International
BDSI
|
84.9 M | - | -4.8 % | $ 255 M | USA |
 |
Cara Therapeutics
CARA
|
-119 M | - | -3.03 % | $ 260 M | USA |
 |
ChemoCentryx
CCXI
|
-132 M | - | - | $ 3.74 B | USA |
 |
Zai Lab Limited
ZLAB
|
-176 M | $ 18.0 | 2.8 % | $ 19.7 B | China |
|
Enlivex Therapeutics Ltd.
ENLV
|
-15 M | $ 1.05 | -3.67 % | $ 21.5 M | Israel |
 |
Enochian Biosciences
ENOB
|
-178 M | - | - | $ 40.5 M | USA |